QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

RECEIPT OF APPROVAL FOR FURTHER EXTENSION OF TIME (I) FOR THE ISSUANCE OF THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 ("FY2019") ANNUAL REPORT AND (II) TO HOLD ITS FY2019 ANNUAL GENERAL MEETING ("FY2019 AGM")

The Board of Directors ("**Board**") of QT Vascular Ltd (the "**Company**" and together with its subsidiaries, the "**Group**") refers to its announcements dated 29 February 2020, 2 April 2020, 14 April 2020 and 8 June 2020 ("**SGX Application Announcements**").

All capitalised terms used in this announcement which are not defined shall have the same meaning ascribed to them in the SGX Application Announcements.

The Board wishes to inform shareholders of the Company ("**Shareholders**") that it has, on 11 June 2020, received a letter from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") setting out, amongst others, that it has no objection to the Company's application on 8 June 2020 for Further EOT to comply with Rule 707(1) of the Catalist Rules (the "**Waiver**"). The approval for the Waiver is subject to:

(i) the Company announcing the Waiver granted, the reasons for seeking the Waiver and the conditions as required under Rule 106 of the Catalist Rules have been satisfied. If the Waiver conditions have not been met on the date of announcement, the Company must make an update announcement when the conditions have been met;

(ii) the Company dispatching the FY2019 Annual Report by 15 July 2020; and

(iii) the Company convening the FY2019 AGM by 31 July 2020.

(together the "**Waiver Conditions**").

In relation to the condition for Waiver Condition (i), please refer to SGX Application Announcement dated 8 June 2020 for the reasons for seeking the Further EOT. The Board wishes to inform Shareholders that the Company will be publishing the FY2019 Annual Report by 15 July 2020 and convene the FY2019 AGM by 31 July 2020. Hence, the Board confirms that the Waiver Conditions have been satisfied.

The Company will make the appropriate announcements as and when there may be material developments in relation to the holding of the FY2019 AGM.

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
11 June 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: sponsorship@ppcf.com.sg).